Search for: "BRISTOL-MYERS SQUIBB COMPANY" Results 21 - 40 of 349
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
27 Jun 2019, 5:50 pm by Stuart P. Meyer
He warned that the draft legislation would lead to “the practice of ‘evergreening,’ in which a drug company obtains a patent on a minor modification to a known drug compound, often years after the initial patent application on the drug was filed. [read post]
26 Jun 2019, 6:36 am by Eileen McDermott
Seventy-two companies and organizations, ranging from Tivo to Bristol-Myers Squibb and from the American Conservative Union to the Alliance of U.S. [read post]
26 Jun 2019, 6:36 am by Eileen McDermott
Seventy-two companies and organizations, ranging from Tivo to Bristol-Myers Squibb and from the American Conservative Union to the Alliance of U.S. [read post]
5 Jun 2019, 7:17 pm by Eileen McDermott
Barbara Fiacco, representing AIPLA; Henry Hadad of Bristol-Myers Squibb and the Intellectual Property Owners Association (IPO) President; Paul Morinville of U.S. [read post]
29 May 2019, 3:34 am
Colombia--The Superintendency of Industry and Commerce has granted registration of the mark “VERSACLOX” (here), on behalf of Bioquimico Pharma S.A.; the trademark was previously owned by BRISTOL MYERS SQUIBB COMPANY but it lapsed in 1982. [read post]
29 Apr 2019, 3:00 am by Liz Dunshee
” Wellington, in a rare public rebuke this year, said it opposed Bristol-Myers Squibb Co. [read post]
24 Apr 2019, 3:00 am by John Jenkins
In late February, Wellington, which runs $359 billion for Vanguard, announced it would oppose Bristol-Myers Squibb ’s plan to acquire Celgene. [read post]
8 Apr 2019, 9:59 pm by Patent Docs
Increases were notanle for Bristol Myers-Squibb and Takeda, while Sanofi and Gilead showed reduced sales. [read post]
30 Mar 2019, 8:49 pm by Patent Docs
Neal Dahiya of Bristol-Myers Squibb Company; Michael Flibbert of Finnegan, Henderson, Farabow, Garrett & Dunner, LLP; Michael Rosato of Wilson Sonsini Goodrich & Rosati will also address strategies for obtaining, and opposing, appellate standing. [read post]
Supreme Court established limitations on personal jurisdiction over non-resident corporate defendants in state court “mass” actions in Bristol-Myers Squibb Co. v. [read post]
9 Feb 2019, 9:50 pm by Patent Docs
Gene Quinn of IPWatchdog and Kevin Noonan of Patent Docs will take a look at the recently announced merger between Bristol-Myers Squibb and Celgene, including what the combined company will look like from a patent perspective, and what competition regulators are likely to be interested in questioning about this acquisition. [read post]
5 Feb 2019, 7:34 am by Lindsay Offutt
Chairman Chuck Grassley and Ranking Member Ron Wyden sent the invitations to AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., Pfizer and Sanofi. [read post]
29 Jan 2019, 3:12 pm by Kevin LaCroix
Several large cases account for much of this effect, including the cases filed against Johnson & Johnson, Facebood, NVIDIA, Bristol-Myers Squibb and Celgene. [read post]
25 Jan 2019, 12:00 am by David Lopez
The first being Bristol Myers Squibb Co’s (BMY) acquisition of Celgene Corp. [read post]
3 Jan 2019, 7:02 am by TIFFANY HSU
Together, the merged companies would have nine pharmaceutical products with more than $1 billion in annual sales each. [read post]
18 Dec 2018, 3:16 pm by Seyfarth Shaw LLP
  Therefore, under the Supreme Court’s rulings in Daimler and Bristol-Myers Squibb, the defendant could be subject to personal jurisdiction in Massachusetts only if the conduct forming the basis for a plaintiff’s claim occurred in Massachusetts. [read post]
9 Nov 2018, 8:01 am by Terry Boyd
Januvia is manufactured by Merck and Byetta is manufactured by Bristol-Myers Squibb. [read post]